Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DreaMed Receives Another FDA Clearance For AI-Powered Diabetes Software

Executive Summary

Israeli firm DreaMed has scored a new US Food and Drug Administration clearance for its AI-based diabetes decision support system Advisor Pro. The clearance enables physicians to use the software for patients with type 1 diabetes using continuous glucose monitoring (CGMs) and blood glucose meters (BGMs).

You may also be interested in...



Abbott And Sanofi To Connect Diabetes Technologies

Abbott and Sanofi are partnering up to develop a new connected diabetes device. The non exclusive collaboration will combine Abbott’s FreeStyle Libre continuous glucose monitoring system with Sanofi’s connected insulin pens and software currently under development.

Medtronic And Novo Nordisk To Collaborate On Diabetes Devices

The companies signed a deal to allow Novo Nordisk’s smart insulin pens to share insulin dosing data with Medtronic’s continuous glucose monitoring devices. Novo Nordisk's smart insulin pens are already compatible with all other major brands of continuous glucose monitors.

Market Intel: CGM Market Competition And Device Interoperability Were Hot Topics At ADA2019

Interoperability and the rising use of continuous glucose monitoring is fueling competition among diabetes device-makers and dominated the conversation at the recent annual ADA meeting.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT125648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel